0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Neurology
Editorial  | 
Cerebrospinal Biomarkers in Alzheimer Disease—Potential Roles as Markers of Prognosis and Neuroplasticity
Steven T. DeKosky, MD; Todd Golde, MD, PhD
JAMA Neurology
Original Investigation  | 
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease
Rawan Tarawneh, MD; Gina D’Angelo, PhD; Dan Crimmins, PhD; et al.
JAMA Neurology
Editorial  | 
Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials
Elizabeth C. Mormino, PhD; Kathryn V. Papp, PhD
JAMA Neurology
Original Investigation  | 
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Anja Soldan, PhD; Corinne Pettigrew, PhD; Qing Cai, MS; et al.